Sodium glucose co-transporter 2 (SGLT2) inhibition via dapagliflozin improves diabetic kidney disease (DKD) over time associatied with increasing effect on the gut microbiota in db/db mice

BACKGROUND: The intestinal microbiota disorder gradually aggravates during the progression of diabetes. Dapagliflozin (DAPA) can improve diabetes and diabetic kidney disease(DKD). However, whether the gut microbiota plays a role in the protection of DAPA for DKD remains unclear. METHODS: To investig...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Jiajia, Chen, Yan, Yang, Huinan, Gu, Leyi, Ni, Zhaohui, Mou, Shan, Shen, Jianxiao, Che, Xiajing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9908601/
https://www.ncbi.nlm.nih.gov/pubmed/36777358
http://dx.doi.org/10.3389/fendo.2023.1026040

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9908601/
https://www.ncbi.nlm.nih.gov/pubmed/36777358
http://dx.doi.org/10.3389/fendo.2023.1026040

Ejemplares similares